Lumefantrine

Generic Name
Lumefantrine
Brand Names
Coartem
Drug Type
Small Molecule
Chemical Formula
C30H32Cl3NO
CAS Number
82186-77-4
Unique Ingredient Identifier
F38R0JR742
Background

Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infe...

Indication

Lumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 k...

Associated Conditions
Uncomplicated Malaria caused by Plasmodium falciparum
Associated Therapies
-
news-shield.com
·

Malaria Developing Resistance to Drug That Saves Children's Lives

Over 600,000 people, mainly young children, die from malaria yearly. New African data shows the malaria parasite gaining resistance to artemisinin, a frontline drug, threatening decades of progress against the disease.

Azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD)

A phase I/II trial compared 3 azithromycin doses in children with severe malaria, randomizing 105 cases to 10, 15, or 20 mg/kg over 5 days, while 50 controls received standard care. The study aimed to determine optimal azithromycin doses for future trials, with co-primary outcomes of CRP change and microbiological cure. Results showed similar CRP reductions across doses, with no significant differences in survival or adverse events. Pharmacokinetic analysis suggested allometric dosing for consistent exposure, contrasting with the trial's mg/kg regimens.

First participants dosed in trial of long-acting malaria preventative

MMV and Quotient Sciences have dosed first participants in a trial of MMV371, a long-acting injectable for malaria prevention, aiming for up to three months of protection with a single dose. The Phase I trial will evaluate safety, tolerability, and pharmacokinetics, with clinical trials in malaria-endemic countries expected to begin in 2026. The final injectable will combine MMV371 with a partner drug to reduce resistance.
© Copyright 2024. All Rights Reserved by MedPath